학술논문
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis
Document Type
Article
Source
In Gynecologic Oncology August 2021 162(2):249-255
Subject
Language
ISSN
0090-8258